Upgrade to SI Premium - Free Trial

Relmada Therapeutics (RLMD)

3.21 -0.15 (4.46%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/5/26)

Latest Headlines

Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: TRAVERSA SERGIO September 11, 2026 7:30 AM - SEC Filing Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: Shenouda Maged September 11, 2026 7:30 AM - SEC Filing Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC August 14, 2026 1:18 PM - SEC Filing Mizuho sees a chance to buy this biotech stock after recent weakness August 14, 2026 1:00 PM - StreetInsider Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD) August 11, 2026 5:10 AM - StreetInsider Relmada Therapeutics (RLMD) Tops Q2 EPS by 8c August 6, 2026 5:05 PM - StreetInsider Form 8-K RELMADA THERAPEUTICS, For: Aug 06 August 6, 2026 4:44 PM - SEC Filing Form 10-Q RELMADA THERAPEUTICS, For: Jun 30 August 6, 2026 4:20 PM - SEC Filing Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update August 6, 2026 4:05 PM - Globe NewsWire Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: BlackRock, Inc. July 29, 2026 3:22 PM - SEC Filing Form 8-K RELMADA THERAPEUTICS, For: Jul 28 July 28, 2026 8:36 AM - SEC Filing Relmada Therapeutics names Bipin Dalmia as chief business officer July 28, 2026 8:31 AM - StreetInsider Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer July 28, 2026 8:30 AM - Globe NewsWire Full Article List